Global Clinical Decision Support System Market to witness a CAGR of 18.4% during 2017-2023

/EIN News/ — NEW YORK, Dec. 15, 2017 (GLOBE NEWSWIRE) — The global clinical decision support system (CDSS) market is expected to witness a CAGR of 18.4%, and is projected to reach USD 1,824.7 million by 2023. The growth of CDSS market is attributed to the increasing government support, growing investment in healthcare IT, and increasing demand for technological advancements in the healthcare sector. The report segments Clinical Decision Support System Market by Component (Software, Hardware, Services), Model (Knowledge-Based Clinical Decision Support Systems, Non-Knowledge-Based Clinical Decision Support Systems), Product (Standalone Clinical Decision Support Systems, Integrated Clinical Decision Support Systems, Standard-Based Clinical Decision Support System, Service Model Based Clinical Decision Support System), Delivery Model (Web-Based Clinical Decision Support System, On Premise Clinical Decision Support System, Cloud Based Clinical Decision Support System), Application (Drug-Drug Interactions, Clinical Guidelines, Drug Allergy Alerts, Clinical Reminders, Drug Dosing Support, Others) and Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa (MEA)). The report studies the global Clinical Decision Support System Market over the forecast period (2017-2023).

Clinical Decision Support System is used to assist clinician by providing some expert opinion or advice for diagnosis and analysis by using patient information. CDSS can provide support to clinicians at various stages, from diagnosis to monitoring and followup. CDSS are designed to integrate patient data with medical knowledge and provide suggestions for the clinician, based on that.

Browse full research report with TOC on “Global Clinical Decision Support System Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2023” at: https://www.energiasmarketresearch.com/global-clinical-decision-support-system-market-outlook/  

Key findings from the report:

  • The global clinical decision support system market is expected to reach USD 1,824.7 million by 2023
  • The knowledge-based clinical decision support system model segment holds the major share of the global CDSS market in 2016, and is expected to hold its dominance during 2017-2023
  • The drug allergy alerts was the largest application of the CDSS market in 2016. The clinical reminders segment is expected to show highest CAGR during the forecast period
  • North America holds the largest share of the global CDSS market and is projected to continue its dominance over the forecast period
  • The Asia-Pacific region is expected to witness highest CAGR during  2017-2023
  • Some of the key companies operating in the CDSS market include Cerner Corporation, EPIC Systems Corporation, Allscripts Healthcare Solutions, Inc., IBM Corporation, Philips Healthcare, Mckesson Corporation, Meditech, Wolters Kluwer Health, among others

Clinical Decision Support System-Primary Drivers

The clinical decision support system market is majorly driven by support initiatives by government organisations across the globe. The Health Information Technology For Economic And Clinical Health (HITECH) Act, 2009, gave huge impetus to the CDSS market in the United states. The financial incentives and stringent rules under the act has encouraged investments and adoption of CDSS in the United states. Moreover, there is a high demand for healthcare Information technologies, such as CDSS in healthcare sector. CDSS based on cloud computing technology offers the flexibility to access patient data regardless of the facility. Healthcare providers adopting improved healthcare technologies are more attractive to patients due to various advantages associated with them.

Clinical Decision Support System Market – Regional insight

North America holds the largest share of the global CDSS market and is projected to continue its dominance over the forecast period, owing to favorable government policies coupled with technological advancements and increasing prevalence of chronic diseases.  Asia-Pacific is projected to achieve high growth rate during the forecast period in the global CDSS market. The factors driving the growth in the region are increased healthcare spending and increasing adoption of information technology in healthcare sector.

About Energias Market Research Private Limited –

Energias Market Research launched with the objective to provide in-depth market analysis, business research solutions, and consultation that is tailored to our client’s specific needs based on our impeccable research methodology.

With a wide range of expertise from various industrial sectors and more than 50 industries that include energy, chemical and materials, information communication technology, semiconductor industries, healthcare and daily consumer goods, etc. We strive to provide our clients with a one-stop solution for all research and consulting needs.

Our comprehensive industry-specific knowledge enables us in creating high quality global research outputs. This wide-range capability differentiates us from our competitors.

Contact:

Manas Nagi

Business Development Manager

For any queries email us: info@energiasmarketresearch.com

To purchase report: sales@energiasmarketresearch.com
Call us: +1-716-239-4915
Visit: https://www.energiasmarketresearch.com/

Primary Logo

Global Wireless Health Market Will Reach USD 427 Billion by 2022: Zion Market Research

According to the report, the global wireless health market accounted for USD 45.40 billion in 2016 and is expected to reach USD 142.48 billion by 2022, growing at a CAGR of around 21% between 2017 and 2022.

/EIN News/ — Sarasota, FL, Dec. 15, 2017 (GLOBE NEWSWIRE) — Zion Market Research has published a new report titled “Global Wireless Health Market by Component (Hardware, Software, & Services), by Technology (WLAN/Wi-Fi, WPAN, WiMAX and WWAN), by Application (Patient-specific, Patient Communication and Support, Physiological Monitoring and Provider/Payer-specific) by End-User (Providers, Payers and Patients/Individuals): Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022”. According to the report, the global wireless health market accounted for USD 45.40 billion in 2016 and is expected to reach USD 142.48 billion by 2022, growing at a CAGR of around 21% between 2017 and 2022. 

Platelets are a component of blood whose function is to form blood clots by sticking together along with the coagulation factors. The main function of platelets is to contribute to hemostasis: the process of stopping bleeding at the site of interrupted endothelium. In addition, they play a crucial role in the inflammation and other pathological situations in conjunction with other cells. With platelet disorders, there may be too many or too few platelets or platelets that do not function well. Some conditions cause changes in both the number and function of platelets. A platelet disorder causes the abnormality in blood clotting function. These disorders can be natural i.e. by birth or acquired during the lifetime due to another disease or condition. Platelet aggregation can be examined through specific tests which have to be conducted before a surgery to diagnose any abnormality in the platelet by using various Wireless Health which in turn expected to fuel the growth in Wireless Health market.

Browse through 59 Tables & 79 Figures spread over 110 Pages and in-depth TOC on “Global Wireless Health Market by Industry Type, Size, Share, Trends and Forecast 2016 – 2022”.

Request Free Sample copy of Global Wireless Health Market Report @ https://www.zionmarketresearch.com/sample/wireless-health-market

The major drivers for Wireless Health market include increasing demand for platelet screening programs to identify diseases like HIV, Dengue etc. In addition, the market is also expected to fuel by demand from a patient population undergoing anti-platelet therapy. Apart from this, increasing geriatric population globally coupled with the growing incidences of target diseases are also expected to boost this market in coming five years. Furthermore, a wide range of new applications of Wireless Health such as assessment of surgical bleeding risk, identification of genetically acquired platelet defects etc. are also expected to drive the market growth within the forecast period. However, the high cost of purchase and limited scope at the level of end users are expected to hamper the market growth in coming five years. In spite of these restraints, research and development in the platelet devices market are expected to be an opportunity for this market in the forecast period.

The global market for wireless health is segmented on the basis of the component, technology, application, and end-user. The component segment is led by software in the year 2016. Technology segment is categorized into WLAN/Wi-Fi, WPAN, WiMAX, and WWAN. This segment was dominated by WPAN technology by accounting for the largest share in this market in 2016. This technology is highly secure and affordable which are the major driving factors for it in the wireless health market. 

Browse the full “ Wireless Health Market by Component (Hardware, Software, & Services), by Technology (WLAN/Wi-Fi, WPAN, WiMAX and WWAN), by Application (Patient-specific, Patient Communication and Support, Physiological Monitoring and Provider/Payer-specific) by End-User (Providers, Payers and Patients/Individuals): Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022” report at  https://www.zionmarketresearch.com/report/wireless-health-market

Based on application, wireless health market segment is categorized into patient-specific, patient communication and support, physiological monitoring and provider/payer-specific. On the basis of end-user, this market is categorized into; providers, payers and patients/individuals. The end-user segment was dominated by the providers by capturing the largest share on this market in 2016. 

North America is expected to witness the fastest growth in global wireless health market in coming five years. In North America, U.S. and Canada are expected to gain the largest market share for wireless health. The North American region has become a lucrative destination for companies engaged in the wireless health due to high investment in the field of healthcare IT due to increasing number of patients of chronic diseases such as cardiovascular and diabetes. In addition, availability of customized wireless healthcare solutions is also a boosting factor in this region for the wireless health market.

Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/wireless-health-market

Europe is expected to capture the second largest position in this market within the forecast period due to the more inclination towards research and development of innovative healthcare technologies and increasing number of chronic disease patients. For example; as per the U.K.’s Centre for Economics and Business Research (CEBR) warned that the cost of cardiovascular disease (CVD) in six major European countries—France, Germany, Spain, Italy, Sweden and the U.K.—will hit 122.6 billion Euros ($161.7 billion) by 2020, up from 102.1 billion Euros 2014.

The Asia Pacific is expected to one of the attractive markets for wireless health within the forecast period. The growth in this region is expected to attribute to the increasing chronic aging population, improving healthcare infrastructure and increasing utilization of various wireless healthcare devices. Latin America, Middle East, and Africa are expected to show positive growth due to increasing government initiatives to adopt the wireless infrastructure in the healthcare sector.

Request customized copy of report @ https://www.zionmarketresearch.com/custom/26

The report presents comprehensive competitive outlook with company profiles of the key players operating in the global market. Key participants profiled in the report include Siemens A.G., Omron Corporation, AT &T, Inc., GE Healthcare, Verizon Communications, Inc., Koninklijke Philips N.V., Polar Electro, Nihon Kohden, Mckesson Corporation and Cerner Corporation among others.

Directly Purchase a copy of report with TOC @ https://www.zionmarketresearch.com/buynow/su/wireless-health-market

For media inquiry contact our sales team @ sales@zionmarketresearch.com

This report segments the Wireless Health market as follows:

Global Wireless Health Market: Component Segment Analysis

  • Software
  • Hardware
  • Services 

Global Wireless Health Market: Technology Segment Analysis

  • WLAN/Wi-Fi
  • WPAN 
  • WiMAX
  • WWAN

Global Wireless Health Market: Application Segment Analysis

  • Patient-specific
  • Patient Communication and Support
  • Physiological Monitoring
  • Provider/Payer-specific 

Global Wireless Health Market: End-User Segment Analysis

  • Providers
  • Payers
  • Patients/Individuals

Global Wireless Health Market: Regional Analysis

  • North America
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
  • The Middle East and Africa

Related Reports:

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research

Follow Us Twitter: https://twitter.com/zion_research

                    Contact Us:
                    
                    Joel John
                    
                    4283, Express Lane, Suite 634-143,
                    Sarasota, Florida 34249, United States
                    Tel: +49-322 210 92714
                    USA/Canada Toll-Free No.1-855-465-4651
                    Email: sales@zionmarketresearch.com
                    Website: https://www.zionmarketresearch.com

Primary Logo

Increasing Prevalence of Hair Disorders are Likely to Impel the Growth of Smart Hairbrush Market in Future

smart hairbrush market

smart hairbrush

“Smart Hairbrush Market: Global Demand Analysis & Opportunity Outlook 2024”

BROOKLYN, NEW YORK, UNITED STATES, December 15, 2017 /EINPresswire.com/ — The global smart hairbrush market is segmented into distribution channel type such as offline stores and online stores. Rising consumer’s preferences for online shopping coupled with availability of smart hairbrush in an online distribution channels is anticipated to fuel the growth of online segments during the forecast period. Further, offline distribution channel is also expected to witness considerable growth during the forecast period owing to availability of smart hairbrush at L’Oreal’s salons and other distribution channels.

Global smart hairbrush market is expected to register a remarkable CAGR over the forecast period. Moreover, the global smart hairbrush market is expected to reach at notable revenue by the end of 2024. Increasing consumer’s inclination towards smart technologies, rising expenditure on personal care and rising concern amongst the people regarding fitness and wellness are some of the major reasons which are predicted to boost the growth of global smart hairbrush market.
European smart hairbrush market is anticipated to grow at massive pace during the forecast period owing to a number of factors such as high spending on personal care and rising adoption of new and innovating technology in Europe region.

Rinsing prevalence of hair disorders

Hair related problems are increasing due to various reasons such as increasing pollution across the globe and unhealthy lifestyle of the population. Further, growing awareness towards hair care and increasing spending on personal care are key factors which are likely to lead consumers to adopt smart hairbrush in order to prevent hair disorders such as hair falls and hair loss in near future.

Request Free Report Sample@ https://www.researchnester.com/sample-request/5/rep-id-223

Technological evolution

Rapid advancements and innovation in smart technologies and rising demand for innovative and effective technologies are likely to allow smart hairbrush market to flourish in near future. Additionally, capabilities of smart hairbrush such as hair health analysis and enhance brushing experience are expected to make smart hairbrush more acceptable amongst the consumers. Further, hair health analysis includes a number of tasks such as hair dryness analysis, hair damage analysis, hair breakage and tangling analysis.

However, high cost of smart hairbrush is a major concern which is expected to hinder the growth of smart hairbrush market over the forecast period.

The report titled “Smart Hairbrush Market: Global Demand Analysis & Opportunity Outlook 2024” delivers detailed overview of the global smart hairbrush market in terms of market segmentation by distribution channel and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Request Free Table of Contents Here: https://www.researchnester.com/toc-request/4/rep-id-223

This report also provides the existing competitive scenario of some of the key players of the global smart hairbrush market which includes company profiling of L’Oréal Group. (The smart hairbrush is a product of three-way collaboration between Kérastase, Withings and L’Oréal’s Research and Innovation Technology Incubator). Further, key potential companies which may enter into manufacturing of smart hair brush are Unilever, Procter & Gamble Co., Estee Lauder Companies Inc., Johnson & Johnson Pvt. Ltd., Avon Products Inc., SHISEIDO Company Ltd. and Kao Corp. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global smart hairbrush market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

About Research Nester

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Read More Information: https://www.researchnester.com/articles/global-smart-hairbrush-market-is-anticipated-to-experience-a-remarkable-growth-during-the-forecast-period-ie-2017-2024-research-nester/223

Ajay Daniel
Research Nester
+1 646 586 9123 / +44 203 608 5919
email us here

What will the industrial Needle Free Insulin Devices Market size and the growth rate be in 2024 ?

Needle Free Insulin Devices Market

Needle Free Insulin Devices Market

“Needle Free Insulin Devices Market: Global Historical Growth (2012-2016) & Future Outlook (2017-2024) Demand Analysis & Opportunity Evaluation”

BROOKLYN, NEW YORK, UNITED STATES, December 15, 2017 /EINPresswire.com/ — The global needle free insulin devices market is segmented into product type such as fillable and prefilled. Among these segments, fillable segment is expected to witness significant demand during the forecast period. Increasing number of diabetic patients and those patients who are not physically able to visit hospital regularly are adopting needle free insulin device at remarkable pace. Further, growing adoption of needle free insulin device amongst the diabetic and disabled patients is envisioned to drive the growth of global needle free insulin device market over the forecast period.

Global needle free insulin devices market is expected to register a robust CAGR over the forecast period. Moreover, the global needle free insulin devices market is expected to reach at notable revenue by the end of 2024. Various features of needle free insulin devices such as faster absorption & action of insulin, portable, reusable, virtually pain free and no risk of needle stick injuries are major factors which are expected to escalate the growth of global needle free insulin devices market.

Furthermore, the homecare segment by end user is likely to grow at remarkable pace during the forecast period. A number of factors such as increasing number of people who have diabetes, high blood sugar and rising prevalence of chronic diseases in old people across the globe are major factors which are augmenting the demand for needle free insulin devices across the globe.

Increasing number of patients who have diabetes and high blood sugar

More than 220 Million people diagnosed by diabetes across the globe. Increasing geriatric population across the globe and growing prevalence of chronic diseases amongst the old people are major concerns in the healthcare industry. Moreover, unhealthy lifestyle of consumers coupled with increasing number of people suffering from diabetes and high blood sugar is a key factor which is envisioned to fuel the demand for needle free insulin devices during the forecast period.

Request Free Report Sample@ https://www.researchnester.com/sample-request/2/rep-id-488

Technological advancements in healthcare sector

Rapid technological advancements in healthcare sector and growing number of diabetic patients are driving the growth of market. Moreover, increasing number of people who are new to diabetes problem and those who have needle phobia and growing number of children suffering from diabetes and high blood sugar problems are anticipated to bolster the growth of global needle free insulin device market.

However, high cost of needle free insulin devices and chances for side-effect are some of the factors that are likely to inhibit the growth of the needle free insulin devices market in the near future.

The report titled “Needle Free Insulin Devices Market: Global Historical Growth (2012-2016) & Future Outlook (2017-2024) Demand Analysis & Opportunity Evaluation” delivers detailed overview of the global needle free insulin devices market in terms of market segmentation by component, by product type, by end-user type and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Request Free Table of Contents Here: https://www.researchnester.com/toc-request/1/rep-id-488

This report also provides the existing competitive scenario of some of the key players of the global needle free insulin devices market which includes company profiling of PharmaJet, Injex Pharma AG, European Pharma Group (InsuJet), ASTS Enterprises Pty Ltd. Key potential companies that may enter into the manufacturing of needle free insulin devices are: Antares Pharma Inc., Endo International PLC, Bioject Medical Technologies Inc., Medical International Technology Inc., National Medical Products Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global needle free insulin devices market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

About Research Nester

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Purchase this Premium Report: https://www.researchnester.com/payment/rep-id-488

Ajay Daniel
Research Nester
+1 646 586 9123 / +44 203 608 5919
email us here

Robotic Process Automation changing the spectrum of business processing, to witness a CAGR of 33.3% during 2017 – 2023

NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) — The global robotic process automation market is expected to grow at a CAGR of 33.3% during 2017 – 2023 to reach 2,821.0 USD by 2023. Factors propelling the growth of robotic process automation market include increasing adoption of RPA technology for enterprise scale deployments, implementation at broader scale enabling easy implementation and high return on investment. The report segments the robotic process automation market by solution (interaction solution, automated solution (business process, industry specific, infrastructure automation, others), decision support and management solution) by Process (rule based and knowledge based), by Type (software tools and services), by Application Services (BFSI, healthcare and life sciences, IT & telecom, transaction intelligence, consumer services, others), and by region (North America, Europe, Asia-Pacific, Rest of the world (ROW)). The report studies the global robotic process automation market over the forecast period (2017-2023).

Robotic process automation technology involves application of smart software to perform high-volume, repeatable tasks such as data processing, entry and integration by reducing humans intervention offering quality, reduced time thus, increasing profit margin. Unlike traditional application processing software, robotic automation offers a platform easing the business processes.

Browse full research report with TOC on “Global Robotic Process Automation Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2023” at: https://www.energiasmarketresearch.com/global-robotic-process-automation-market-outlook/

Key findings from global robotic process automation market

  • The automated solution is accounted to hold for largest share of robotic process automation market in 2016. Further, the infrastructure automation is expected to register high growth rate on account of increasing implementation of RPA technology in shared service organizations such as BPOs
  • Banking financial services and insurance (BFSI) application services is expected to grow at highest rate. The BFSI sector is in continuous effort to reduce the operation cost and increasing profit margins increasing the adoption rate of RPA technology
  • Geographically, North America is the largest market adopting RPA technology in the small and large scale businesses. The growth in the region is primarily due to presence of large players and continuous development of the RPA technology over the past few years
  • The adoption of RPA technology in Asia-Pacific region is set to register high CAGR over the forecast period. The increasing adoption  and spending in healthcare, automotive and retail services drives the demand for the implementation of RPA in the region
  • Key players in robotic process automation Market are Peg systems Inc., Blue Prism PLC, Verint System Inc., Xerox Corporation, IBM, Arago Us, Inc., Accenture, Thoughtonomy Ltd., Ipsoft, Inc., Soft motive Ltd. among others.

Robotic Process automation – Alternate to outsourcing

RPA being an emerging technology is being adopted across various business processes across the globe. Robotics process automation (RPA) is a further step to the evolution of business process outsourcing. The technology enables to reduce the cost of operations by reducing requirement of employees to perform high volume rule based task. RPA technology offers companies an alternative to outsourcing and has high impact on reduced cost, making organizations to adopt the technology at high rate and broader scale across the globe. 

/EIN News/ — Robotic Process automation Market – Regional Insight

North America region held the major market share in robotics process automation market. The growth in the region is attributed to adoption of RPA technology at broader scale. Further, the presence of major players in the region propels the growth for the robotics process automation implementation. The implementation of RPA software by small and medium enterprises at higher rate led to an increasing market share in the region. The implementation of RPA software and tools in BFSI sector is increasing rapidly in U.S. increasing the market size in the region. The greater adoption by financial, healthcare, human resource and banking sector drives the growth of RPA market in Asia-Pacific region. Further, Robotic Process Automation (RPA) software continues to grow significantly in the Asia-Pacific region, driven by trend opted by enterprises to create more of digital workforce in order to reduce the cost.

About Energias Market Research

Energias Market Research launched with the objective to provide in-depth market analysis, business research solutions, and consultation that is tailored to our client’s specific needs based on our impeccable research methodology.

With a wide range of expertise from various industrial sectors and more than 50 industries that include energy, chemical and materials, information communication technology, semiconductor industries, healthcare and daily consumer goods, etc. We strive to provide our clients with a one-stop solution for all research and consulting needs.

Our comprehensive industry-specific knowledge enables us in creating high quality global research outputs. This wide-range capability differentiates us from our competitors.

Contact:

Manas Nagi

Business Development Manager

For any queries email us: info@energiasmarketresearch.com

To purchase report: sales@energiasmarketresearch.com
Call us: +1-716-239-4915
Visit: www.energiasmarketresearch.com

Primary Logo

Toronto Exchanges Stock Review, Air Canada, WestJet Airlines, Chorus Aviation, and Exchange Income

LONDON, UK / ACCESSWIRE / December 15, 2017 / Active-Investors free stock reports for this morning include these Toronto Exchanges’ equities from the Airlines industry: Air Canada, WestJet Airlines, Chorus Aviation, and Exchange Income. Access our complimentary up-to-the-minute research reports by becoming an online member now:

www.active-investors.com/registration-sg

The S&P/TSX Composite Index lost 120.13 points, or 0.74%, to close Thursday’s trading session at 16,016.46. The TSX Venture Exchange shaved off 0.37 points, or 0.05%, to finish at 798.20.

Moreover, the Industrials index was down by 0.57%, closing at 238.85.

Today’s stocks of interest consist of Air Canada (TSX: AC), WestJet Airlines Ltd (TSX: WJA), Chorus Aviation Inc. (TSX: CHR), and Exchange Income Corporation (TSX: EIF). Click the link below to view a sample of the free research report that will be available to you as a member of Active-Investors:

www.active-investors.com/registration-sg

Air Canada

Saint-Laurent, Canada headquartered Air Canada’s stock edged 0.87% lower, to finish Thursday’s session at $25.12 with a total volume of 1.47 million shares traded. Over the last month and the previous three months, Air Canada’s shares have gained 9.12% and 5.50%, respectively. Furthermore, the stock has rallied 80.33% in the past year. The Company’s shares are trading above its 50-day and 200-day moving averages. Air Canada’s 50-day moving average of $24.61 is above its 200-day moving average of $22.75. Shares of the Company, which provides the US transbonder and international airline services, are trading at a PE ratio of 3.73. View the research report on AC.TO at:

www.active-investors.com/registration-sg/?symbol=AC

WestJet Airlines Ltd

On Thursday, shares in Calgary, Canada-based WestJet Airlines Ltd recorded a trading volume of 139,611 shares. The stock ended the day 1.78% lower at $26.98. WestJet Airlines’ stock has advanced 4.90% in the last month and 3.37% in the previous three months. Furthermore, the stock has gained 18.65% in the past one year. The Company’s shares are trading above its 50-day and 200-day moving averages. The stock’s 50-day moving average of $26.37 is above its 200-day moving average of $25.50. Shares of WestJet Airlines, which provides scheduled airline services and travel packages, are trading at a PE ratio of 10.94. Get the free report on WJA.TO at:

www.active-investors.com/registration-sg/?symbol=WJA

Chorus Aviation Inc.

On Thursday, shares in Dartmouth, Canada-based Chorus Aviation Inc. ended the session 1.35% lower at $9.52 with a total volume of 353,286 shares traded. Chorus Aviation’s shares have gained 11.48% in the last three months and 46.46% in the previous year. The stock is trading above its 50-day and 200-day moving averages. Furthermore, the stock’s 50-day moving average of $9.50 is greater than its 200-day moving average of $8.42. Shares of the Company, which through its subsidiaries, engages in the airline business in Canada and the US, are trading at a PE ratio of 7.50. Access the most recent report coverage on CHR.TO at:

www.active-investors.com/registration-sg/?symbol=CHR

Exchange Income Corp.

Winnipeg, Canada headquartered Exchange Income Corp.’s stock closed the day 0.54% higher at $35.46. The stock recorded a trading volume of 55,573 shares. Exchange Income’s shares have gained 10.67% in the last month and 7.45% in the past three months. The Company’s shares are trading above their 50-day and 200-day moving averages. Moreover, the stock’s 50-day moving average of $35.01 is greater than its 200-day moving average of $32.60. Shares of the Company, which engages in aerospace and aviation services and equipment, and manufacturing businesses worldwide, are trading at a PE ratio of 16.52. Today’s complimentary report on EIF.TO can be accessed at:

www.active-investors.com/registration-sg/?symbol=EIF

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Wired News – CHF Solutions Partners with TRANSMEDIC for Marketing and Distribution of Aquadex FlexFlow(R) System in Singapore

Stock Monitor: PAVmed Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 15, 2017 / Active-Investors issued a free report on CHF Solutions, Inc. (NASDAQ: CHFS), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=CHFS as the Company’s latest news hit the wire. On December 13, 2017, the Company announced that is has signed an international distribution agreement with Singapore-based TRANSMEDIC Pte Ltd. The agreement is for the marketing, distribution and providing sales support for CHF Solutions’ Aquadex FlexFlow® System in Singapore. The agreement will allow CHF Solutions to expand its market reach in Singapore for its product. Sign up now for our free research reports at:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for PAVmed Inc. (NASDAQ: PAVM), which also belongs to the Healthcare sector as the Company CHF Solutions. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=PAVM

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, CHF Solutions most recent news is on our radar and we have decided to include it on our blog post. Today’s free coverage is available at:

www.active-investors.com/registration-sg/?symbol=CHFS

Commenting on the choosing of TRANSMEDIC for marketing and distribution of its Aquadex FlexFlow® System in Singapore, John Erb, CEO of CHF Solutions, said:

“TRANSMEDIC has the market reach and service breadth to meet our expansion goals as we continue to execute our US and international growth plans. We have been in contact with healthcare providers that already own Aquadex FlexFlow® consoles, and we look forward to TRANSMEDIC being able to service those units, bring them back into use and expanding the usage in the area.”

About CHF Solutions’ Aquadex FlexFlow®

The Aquadex FlexFlow® system is a small and portable medical device designed to remove excess fluid (primarily excess salt and water) from patients suffering from hypervolemia, or fluid overload and who have failed diuretic therapy. The system uses a single-use, disposable auto-loading blood filter circuit, and it is simple, safe, and can precisely remove excess fluids from patients. Additionally, the system is better than the renal replacement devices currently being used for ultrafiltration. The Aquadex FlexFlow® system allows medical practitioners to specify and control the amount of fluid to be extracted at a safe, predictable, and effective rate. The use of this system does not have any major impact on electrolyte balance, blood pressure, or heart rate of patients.

About CHF Solutions Inc.

Eden Prairie, Minnesota-based CHF Solutions is an early-stage medical device company which develops cardiac and coronary disease products primarily in US. It is focused on commercializing the Aquadex FlexFlow® system, a medical device designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy and require hospitalization. All treatments are to be administered by a healthcare provider under prescription from a physician, both of whom having received training in extracorporeal therapies. The Company’s mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. The Company also has wholly owned subsidiaries in Australia and Ireland.

About TRANSMEDIC Pte Ltd.

Singapore-based TRANSMEDIC was founded in 1980 by Lee Thian Soo, Teo Kee Meng. and Seah Kerk Chuan. It is a premier medical technology sales and distribution Company that is engaged in the sales, distribution of medical devices, and highly specialized drugs across hospitals, clinics, and health-centers in Asia. The Company offers a wide range of high quality medical products from 40 different Companies and provides education and training plus technical support and maintenance for these advanced technological devices. The Company’s operations are spread across 7 countries in Southeast Asia and is supported by a team of 400 people.

Stock Performance Snapshot

December 14, 2017 – At Thursday’s closing bell, CHF Solutions’ stock dropped 4.57%, ending the trading session at $3.76.

Volume traded for the day: 588.75 thousand shares.

After yesterday’s close, CHF Solutions’ market cap was at $7.07 million.

The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Free Research Report as Ashland’s Revenue Grew 17% and Adjusted EPS Surged 63%

LONDON, UK / ACCESSWIRE / December 15, 2017 / Active-Investors free earnings report on Ashland Global Holdings Inc. (NYSE: ASH) (“Ashland”) has freshly been issued to its members, and you can also sign up to view this report at www.active-investors.com/registration-sg/?symbol=ASH. The Company posted its financial results on November 06, 2017, for the fourth quarter of the fiscal year 2017. The Company’s revenue and adjusted EPS surpassed analysts’ expectations. Register today and get free access to our complimentary member’s area where many more reports are available:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Ashland Global Holdings most recent news is on our radar and we have decided to include it on our blog post. Today’s free coverage is available at:

www.active-investors.com/registration-sg/?symbol=ASH

Earnings Highlights and Summary

For the three months ended September 30, 2017, Ashland’s revenues increased 17% to $880 million from $754 million in Q4 FY16. The Company’s revenue numbers surpassed analysts’ expectations of $869.96 million.

During Q4 FY17, Ashland’s gross profit increased 28.6% to $234 million from $182 million in the same period of last year. For the reported quarter, the Company’s gross margin increased 250 basis points to 26.6% of revenue from 24.1% of revenue in the third quarter of last year.

During Q4 FY17, Ashland’s earnings before interest, tax, depreciation, and amortization (EBITDA) was positive $106 million versus negative $141 million in the comparable period of last year. During Q4 FY17, Ashland’s adjusted EBITDA increased 13% to $161 million from $143 million in Q4 FY16. For the reported quarter, the Company’s adjusted EBITDA margin decreased 70 basis points to 18.3% of revenue from 19.0% of revenue in the third quarter of last year.

During Q4 FY17, Ashland’s operating income was positive $34 million compared to negative $272 million in the corresponding period of last year. For the reported quarter, the Company’s adjusted operating income increased 22% to $84 million from $69 million in Q4 FY16.

During Q4 FY17, Ashland’s earnings before tax (EBT) was positive $3 million compared to negative $330 million in the same period of last year.

For the reported quarter, Ashland’s net loss was $53 million compared to a net loss of $344 million in Q4 FY16. During Q4 FY17, the Company’s diluted earnings per share (EPS) was negative $0.84 versus negative $5.56 in the comparable period of last year. For the reported quarter, Ashland’s adjusted net income increased 67% to $50 million on a y-o-y basis from $30 million in Q4 FY16. During Q4 FY17, the Company’s adjusted diluted EPS increased 63% to $0.78 on a y-o-y basis from $0.48 in Q4 FY16, surpassing analysts’ expectations of $0.68.

Segment Details

Specialty Ingredients – During Q4 FY17, the Company’s Specialty Ingredients segment’s revenue increased 12% to $598 million from $532 million in the corresponding period of last year. For the reported quarter, the segment’s operating income decreased 9.0% to $61 million from $67 million in Q4 FY16. For the reported quarter, the segment’s sales per shipping day increased 14.5% to $9.5 million from $8.3 million in the fourth quarter of 2016. For the reported quarter, the segment’s sales were 80,500 metric tons compared to 79,600 metric tons in Q4 FY16.

Composites – During Q4 FY17, the Company’s Composites segment’s revenue increased 35% to $219 million from $162 million in the same period of last year. For the reported quarter, the segment’s operating income increased 89% to $17 million from $9 million in Q4 FY16. For the reported quarter, the segment’s sales per shipping day increased 140% to $3.5 million from $2.5 million in the fourth quarter of 2016. For the reported quarter, the segment’s sales were 94,800 metric tons compared to 75,200 metric tons in Q4 FY16.

Intermediates and Solvents – During Q4 FY17, the Company’s Intermediates and Solvents segment’s revenue increased 5% to $63 million from $60 million in the comparable period of last year. For the reported quarter, the segment’s operating loss was $4 million compared to an operating loss of $186 million in Q4 FY16. For the reported quarter, the segment’s sales per shipping day increased 11.1% to $1.0 million from $0.9 million in the fourth quarter of 2016. For the reported quarter, the segment’s sales were 27,200 metric tons compared to 33,500 metric tons in Q4 FY16.

Balance Sheet

As on September 30, 2017, Ashland’s cash and cash equivalents decreased 44.3% to $566 million from $1.02 billion as on December 31, 2016. For the reported quarter, the Company’s long-term debt increased 11.1% to $2.58 billion from $2.33 billion in Q4 FY16.

For the reported quarter, the Company’s accounts receivable increased 15.7% to $612 million from $529 million in Q4 FY16. For the reported quarter, the Company’s trade and other payable increased 8.8% to $409 million from $376 million in Q4 FY16.

During Q4 FY17, the Company’s cash provided by operating activities increased 2.9% to $140 million from $136 million in the corresponding period of last year. During Q4 FY17, the Company’s cash provided by operating activities increased 24.1% to $67 million from $54 million in Q4 FY16.

Outlook

For FY18, the Company expects adjusted diluted EPS to be in the range of $3.20 – $3.40, and free cash flow to be $220 million.

Stock Performance Snapshot

December 14, 2017 – At Thursday’s closing bell, Ashland Global Holdings’ stock dropped 1.32%, ending the trading session at $70.06.

Volume traded for the day: 419.14 thousand shares.

Stock performance in the last month – up 5.08%; previous three-month period – up 9.43%; past twelve-month period – up 27.76%; and year-to-date – up 31.02%

After yesterday’s close, Ashland Global Holdings’ market cap was at $4.34 billion.

The stock has a dividend yield of 1.28%.

The stock is part of the Basic Materials sector, categorized under the Chemicals – Major Diversified industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Wired News – BioLife’s CryoStor(R) Freeze Media and HypoThermosol® Cell Storage Adopted by Iovance Biotherapeutics

Stock Monitor: Iovance Biotherapeutics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 15, 2017 / Active-Investors issued a free report on BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife”), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=BLFS as the Company’s latest news hit the wire. On December 13, 2017, the Company declared that it has executed an agreement to supply its CryoStor® cell freeze media and HypoThermosol® cell storage and shipping media to Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance”). Iovance is currently conducting several clinical trials for tumor infiltrating lymphocyte (TIL) therapies targeting multiple solid tumor types. Sign up now for our free research reports at:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, BioLife Solutions most recent news is on our radar and we have decided to include it on our blog post. Today’s free coverage BLFS and IOVA are available at:

www.active-investors.com/registration-sg/?symbol=BLFS

www.active-investors.com/registration-sg/?symbol=IOVA

BioLife’s Proprietary Bio-Preservation Media Products Being Adopted Due to Improved Yield

Commenting on the collaboration, Mike Rice, President and Chief Executive Officer (CEO) of BioLife, stated that it was very rewarding to see the Company’s proprietary bio-preservation media products being broadly adopted in the regenerative medicine market, due to the improved yield and extended shelf life its IP platform can offer to its customers.

BioLife’s Long-Term Supply Agreements for CryoStor® Use

CryoStor® and HypoThermosol® have been incorporated into the manufacturing processes of at least 250 regenerative medicine applications, including numerous late-stage clinical trials. Reports suggest that till date, the Company has executed long-term supply agreements with the following Companies:

  • On November 29, 2017, the Company executed a new confidential agreement to supply its proprietary CryoStor® cell freeze media to a leading T cell therapy customer.
  • In July 2017, BioLife entered into a long-term supply agreement with Celyad. BioLife’s CryoStor® clinical grade cell freeze media is incorporated into Celyad’s manufacturing process for its Natural Killer Receptor based T-Cell platform.
  • The Company entered into a supply agreement with Adaptimmune Therapeutics Plc, for the use of CryoStor® in SPEAR T-Cell Platform, on June 14, 2017.
  • In December 2016, BioLife signed a ten-year supply agreement with TissueGene. The former’s CryoStor® clinical grade cell freeze media is incorporated into TissueGene’s manufacturing process for Invossa.
  • The Company entered into a ten-year supply agreement with Bellicum Pharmaceuticals, for CryoStor® use in Cellular Immunotherapies, in August 2016.
  • On July 11, 2016, BioLife signed a ten-year supply agreement with Kite Pharma. The agreement provided for Kite’s supply of BioLife’s CryoStor® clinical grade freeze media for cells and tissues, which is embedded in Kite’s manufacturing process for KTE-C19.
  • In June 2014, Nice, France-based TxCell, adopted BioLife’s CryoStor® clinical grade cell freezing media for use in their European Phase-IIb clinical trial of Ovasave immunotherapy in refractory Crohn’s Disease.

About CryoStor® Cell Freeze Media and HypoThermosol® Cell Storage

CryoStor® cryopreservation freeze media products have been designed to mitigate temperature-induced molecular cell stress responses during freezing and thawing, and are based on the novel HypoThermosol® formula. These products have proven to be much more effective in reducing post-preservation necrosis and apoptosis compared to commercial and home-brew isotonic and extracellular formulations.

HypoThermosol® bio-preservation media is a novel, engineered, optimized hypothermic storage and shipping media product. Serum-free, protein-free HypoThermosol® is designed to provide maximum storage and shipping stability for biologics at 2-8°C. This proprietary, optimized formulation mitigates temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications.

About BioLife Solutions, Inc.

Founded in 1987, BioLife is a leading developer, manufacturer, and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, and a related cloud hosted bio-logistics cold chain management app for smart shippers. The Company is based in Bothell, Washington.

About Iovance Biotherapeutics, Inc.

Established in 2007 and headquartered in San Carlos, California, Iovance is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes. The Company’s lead product candidate is an autologous, ready-to-infuse cell therapy that has demonstrated distinctive efficacy in the treatment of metastatic melanoma.

Stock Performance Snapshot

December 14, 2017 – At Thursday’s closing bell, BioLife Solutions’ stock climbed 3.72%, ending the trading session at $5.85.

Volume traded for the day: 60.56 thousand shares.

Stock performance in the last three-month – up 20.62%; previous six-month period – up 156.58%; past twelve-month period – up 272.61%; and year-to-date – up 263.29%

After yesterday’s close, BioLife Solutions’ market cap was at $77.57 million.

The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Free Research Report as Cardinal Health’s Adjusted EPS Beat Expectations

LONDON, UK / ACCESSWIRE / December 15, 2017 / Active-Investors free earnings report on Cardinal Health, Inc. (NYSE: CAH) (“Cardinal”) has freshly been issued to its members, and you can also sign up to view this report at www.active-investors.com/registration-sg/?symbol=CAH. The Company posted its first quarter fiscal 2018 results on November 06, 2017. The leading global integrated healthcare services provider’s revenue grew 2% on a y-o-y basis. Register today and get free access to our complimentary member’s area where many more reports are available:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Cardinal Health most recent news is on our radar and we have decided to include it on our blog post. Today’s free coverage is available at:

www.active-investors.com/registration-sg/?symbol=CAH

Earnings Highlights and Summary

In Q1 FY18, Cardinal’s revenues grew 1.88% to $32.64 billion on a y-o-y basis compared to $32.04 billion in Q1 FY17, missing analysts’ estimates of $33.43 billion.

The Company’s gross margin was $1.67 billion for the reported quarter compared to $1.59 billion in Q1 FY17, increasing 5.15% on a y-o-y basis. Cardinal’s selling, general, and administrative expenses (SG&A) were $1.06 billion for the reported quarter compared to $920.00 million in Q1 FY17, increasing 15.43% on a y-o-y basis due to acquisitions and costs related to a multi-year project to replace the Pharmaceutical segment’s finance and operating information systems.

Cardinal’s operating earnings were $262.00 million in Q1 FY18 compared to $535.00 million in Q1 FY17, declining 51.03%. The Company’s non-GAAP operating earnings were $610.00 million in Q1 FY18 compared to $669.00 million in Q1 FY17, declining by 8.81%.

Cardinal’s net income was $115.00 million for the reported quarter compared to $309.00 million in Q1 FY17, dropping 62.78%. The diluted earnings per share (EPS) was $0.36 in Q1 FY18 compared to $0.96 in Q1 FY17, reflecting a decline of 62.50%.The Company’s EPS, adjusted for amortization and restructuring costs, declined 12.10% to $1.09 in Q1 FY18 compared to $1.24 in Q1 FY17, beating analysts’ estimates of $1.01.

Segment Details

Cardinal’s Pharmaceutical segment reported revenues of $28.92 billion in Q1 FY18 compared to $28.76 billion in Q1 FY17, slightly increasing by 0.55% due to a sales growth from specialty and pharmaceutical distribution customers. The segment’s profit was $467.00 million in the reported quarter compared to $534.00 million in Q1 FY17, declining by 12.55% due to a negative impact of generic pharmaceutical customer pricing changes.

Cardinal’s Medical segment reported revenues of $3.72 billion in Q1 FY18 compared to $3.28 billion in Q1 FY18, advancing by 13.57% due to contributions from acquisitions of $333.00 million, inclusive of the Patient Recovery Business acquisition. The segment’s profit was $129.00 million in Q1 FY18 compared to $127.00 million in Q1 FY17, declining 1.57% on a y-o-y basis, due to an unfavorable cost of products sold impact from the fair value step-up of inventory acquired with the Patient Recovery Business.

Cash Matters

Cardinal had cash and cash equivalents of $1.18 billion in Q1 FY18 compared to $2.00 billion in Q1 FY17. The Company’s net inflow from operating activities was $1.18 billion for the reported quarter compared to $104.00 million in Q1 FY17.

During Q1 FY18, Cardinal repurchased $150.00 million of its common shares, funded by available cash and short-term borrowings. On July 29, 2017, the Company acquired the Patient Recovery Business from Medtronic Plc for $6.10 billion in cash, funded by a $4.50 billion of new long-term debt issued in June 2017.

Outlook

For the fiscal year 2018, Cardinal anticipates non-GAAP diluted EPS to be in the range of $4.85 – $5.10, and expects the Pharmaceutical segment’s profit to be less than in the fiscal year 2017, due to generic pharmaceutical customer pricing changes.

Stock Performance Snapshot

December 14, 2017 – At Thursday’s closing bell, Cardinal Health’s stock was marginally down 0.36%, ending the trading session at $60.35.

Volume traded for the day: 3.27 million shares.

Stock performance in the last month – up 5.75%

After yesterday’s close, Cardinal Health’s market cap was at $19.42 billion.

Price to Earnings (P/E) ratio was at 17.58.

The stock has a dividend yield of 3.07%.

The stock is part of the Services sector, categorized under the Drugs Wholesale industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors